The short version
- Why people research itSoft-tissue and gut repair, reduced inflammation, angiogenesis and faster recovery from injury.
- What the evidence isGenuine randomized human trials — ARA-290 (cibinetide) was studied in sarcoidosis-associated small-fiber neuropathy and in type 2 diabetic neuropathy.
- What to watchBlood pressure creeping up or new pounding headaches.
How ARA-290 works
Non-erythropoietic EPO-derived peptide that activates the innate repair receptor — anti-inflammatory and nerve-repair without raising red cells.
ARA 290 is eleven amino acids cut out of the tertiary structure of erythropoietin, and the entire point of it is a receptor it does not hit. The sequence is pyroglutamate followed by Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser — a stretch of erythropoietin’s helix B that faces away from the surface EPO uses to bind its own receptor.
The receptor distinction is the drug. Erythropoietin acts through two different receptor assemblies. The EPOR homodimer drives erythropoiesis — that is the receptor that makes red cells and raises hematocrit.
- Injectable
On the goal map: Satellite cells & local repair (Build muscle & strength)
Research on ARA-2905 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Evidence on file: Human trials (neuropathy).
Human clinical evidence
Genuine randomized human trials — ARA-290 (cibinetide) was studied in sarcoidosis-associated small-fiber neuropathy and in type 2 diabetic neuropathy. In the largest trial (64 patients, 28 days), cibinetide significantly increased corneal nerve fiber area versus placebo (P = 0.012). Pain fell, but not significantly more than on placebo (P = 0.157).
Development did not continue to approval. That is a funding and commercial outcome, not a refutation — the neuropathy signal was one of the more promising in a field with very little that works.
Correlative data
Small but consistent community use for neuropathic pain and inflammation, where reported experience tracks the trials — slow-building relief over weeks rather than an acute effect.
How the mechanism reads
An 11-amino-acid peptide derived from erythropoietin's helix B — it binds the innate repair receptor (EPOR/βcR heterodimer) rather than the classical EPO receptor.
MechanisticThat receptor split is the entire design: it delivers EPO's tissue-protective and anti-inflammatory signaling without raising hematocrit, which is what makes EPO itself unusable for this purpose.
Mechanistic
Sources
- Brines M, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Molecular Medicine 2015 · PMID 25387363
- Swartjes M, et al. ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response. Molecular Pain 2014 · PMID 24529189
- Lois N, et al. A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. Journal of Clinical Medicine 2020 · PMID 32674280
- Nairz M, et al. Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis. Scientific Reports 2017 · PMID 29026145
- Awida Z, et al. The Non-Erythropoietic EPO Analogue Cibinetide Inhibits Osteoclastogenesis In Vitro and Increases Bone Mineral Density in Mice. International Journal of Molecular Sciences 2021 · PMID 35008482
ARA-290 safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Active cancer, since tissue-protective EPO-receptor signaling is also used by tumor cells.
- History of blood clots or an already high hematocrit.
- Uncontrolled hypertension, a known erythropoietin-class concern.
- Pregnancy or breastfeeding, which no trial covered.
What’s expected
- Neuropathic pain and nerve-fiber signs improve gradually in diabetic and sarcoidosis neuropathy trials.
- Lower inflammatory tone without extra red blood cells.
- Transient site reactions or headache.
Watch for
- Blood pressure creeping up or new pounding headaches.
- One calf that swells, aches or turns red.
- Hematocrit climbing on a routine test.
Labs that tell you it’s working
- Complete Blood Count: hematocrit and hemoglobin should NOT rise, which is the design test for this molecule.
- hs-CRP: shows whether the innate repair receptor dampens inflammation.
- HbA1c: the neuropathy trials enrolled people with diabetes.
Non-erythropoietic EPO-derived helix B peptide that engages the EPOR/CD131 innate repair receptor, not the red-cell EPOR homodimer. PMID 32674280 PMID 25387363
Bloodwork to runHow you would know it is working: 8 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
ARA-290 FAQ4 common questions
- Is ARA-290 approved for human use?
- No. ARA-290 is a research compound.
- What is ARA-290 researched for?
- Soft-tissue and gut repair, reduced inflammation, angiogenesis and faster recovery from injury.
- Which labs show whether it's doing anything?
- Complete Blood Count; hs-CRP; HbA1c: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for ARA-290: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.




